文献速递妇科

FOXL2与TERT启动子突变ctDNA用于成人颗粒细胞瘤疾病监测

FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
PubMed 文献 · Gynecol Oncol · 2021-06-01

这项多中心前瞻性研究纳入21例携带FOXL2 402C>G和/或TERT启动子突变的成人颗粒细胞瘤患者,连续采集110份血浆样本,用微滴数字PCR检测ctDNA。结果显示78.6%的FOXL2突变患者可检出FOXL2突变ctDNA,TERT突变ctDNA检出率较低,两者水平在多数患者中与疾病进展和治疗反应相关。

要点

  • FOXL2突变ctDNA在多数aGCT患者血浆中可检出,具监测潜力。
  • TERT启动子突变ctDNA仅在部分患者中检出。
  • FOXL2与TERT突变ctDNA水平多与疾病进展和治疗反应相关。

核心结论

  • FOXL2突变ctDNA在多数aGCT患者中存在,TERT启动子突变ctDNA见于较小部分患者,两者检测可能对疾病监测有临床价值。

研究设计与样本

  • 全国多中心前瞻性研究,连续采集21例原发性(n=3)或复发性(n=18)aGCT患者的110份血浆样本,患者携带FOXL2 402C>G和/或TERT启动子(C228T或C250T)突变。
  • 采用微滴数字PCR检测血浆游离DNA中FOXL2或TERT突变ctDNA,并将突变ctDNA分数丰度与临床参数进行相关性分析。

主要发现

  • 在14例确认FOXL2突变的aGCT患者中,11例(78.6%)血浆检出FOXL2突变ctDNA。
  • TERT C228T突变ctDNA在10例中检出4例(40%),TERT C250T突变ctDNA在2例中检出1例。
  • 多数患者中FOXL2突变ctDNA和TERT启动子突变ctDNA水平与疾病进展和治疗反应相关。

临床怎么用

  • 对携带FOXL2或TERT启动子突变的aGCT患者,可考虑连续检测血浆ctDNA以辅助监测疾病进展和治疗反应。

局限性

  • 样本量小(21例患者、110份血浆样本),TERT突变亚组例数更少,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Adult granulosa cell tumors (aGCTs) represent a rare, hormonally active subtype of ovarian cancer that has a tendency to relapse late and repeatedly. Current serum hormone markers are inaccurate in reflecting tumor burden in a subset of aGCT patients, indicating the need for a novel biomarker. We investigated the presence of circulating tumor DNA (ctDNA) harboring a FOXL2 or TERT promoter mutation in serial plasma samples of aGCT patients to determine its clinical value for monitoring disease. METHODS: In a national multicenter study, plasma samples (n = 110) were prospectively collected from 21 patients with primary (n = 3) or recurrent (n = 18) aGCT harboring a FOXL2 402C > G and/or TERT (C228T or C250T) promoter mutation. Circulating cell-free DNA was extracted and assessed for ctDNA containing one of either mutations using droplet digital PCR (ddPCR). Fractional abundance of FOXL2 mutant and TERT mutant ctDNA was correlated with clinical parameters. RESULTS: FOXL2 mutant ctDNA was found in plasma of 11 out of 14 patients (78.6%) with aGCT with a confirmed FOXL2 mutation. TERT C228T or TERT C250T mutant ctDNA was detected in plasma of 4 of 10 (40%) and 1 of 2 patients, respectively. Both FOXL2 mutant ctDNA and TERT promoter mutant ctDNA levels correlated with disease progression and treatment response in the majority of patients. CONCLUSIONS: FOXL2 mutant ctDNA was present in the majority of aGCT patients and TERT promoter mutant ctDNA has been identified in a smaller subset of patients. Both FOXL2 and TERT mutant ctDNA detection may have clinical value in disease monitoring.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Groeneweg JW, Roze JF, Peters EDJ, et al. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring. Gynecol Oncol. 2021. PMID: 34083028. doi:10.1016/j.ygyno.2021.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。